Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KYV-101 in Non-relapsing and Progressive Forms of Multiple Sclerosis
NCT06138132Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mivocabtagene autoleucel in multiple sclerosis (MS), sponsored by Stanford University. Primary endpoint: Dose Limiting Toxicities at 12 months. Started Apr 2024; status: recruiting.
02
Drugs
mivocabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06138132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06138132.